Allogene Therapeutics (ALLO) Shares Outstanding (2018 - 2026)

Allogene Therapeutics has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $244.8 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 11.99% year-over-year to $244.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $244.8 million (up 11.99% YoY) and the FY2025 annual result came in at $229.4 million, up 8.11% from the prior year.
• Shares Outstanding (Entity) climbed to $244.8 million in Q1 2026 per ALLO's latest filing, from $229.4 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $244.8 million in Q1 2026 and troughed at $143.6 million in Q1 2022.
• A 5-year average of $186.0 million and a median of $170.5 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Entity) gained 1.12% in 2022, then climbed 28.25% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $144.4 million in 2022, then grew by 16.76% to $168.6 million in 2023, then gained by 25.83% to $212.2 million in 2024, then grew by 8.11% to $229.4 million in 2025, then climbed by 6.71% to $244.8 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $244.8 million, $229.4 million, and $223.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.